Chompoonuch SawaengsakYasuko MoriKoichi YamanishiPotjanee SrimanoteWanpen ChaicumpaAmpol MitrevejNuttanan SinchaipanidMahidol UniversityNational Institute of Biomedical InnovationKobe University School of MedicineThammasat University2018-11-092018-11-092014-10-01International Journal of Pharmaceutics. Vol.473, No.1-2 (2014), 113-12518733476037851732-s2.0-84904332164https://repository.li.mahidol.ac.th/handle/20.500.14594/34897An egg-free and broadly effective influenza vaccine that can be produced rapidly, adequately and cost-effectively is needed. In this study, chitosan-associated DNAs prepared at various nitrogen/phosphate charge (N/P) ratios were studied for their physicochemical properties, stability, cytotoxicity, and protein expression ability. The chitosan-DNA complexes (chitoplexes) of the N/P ratio 2 had the required characteristics including optimal size range, positive surface charge, high DNA association efficiency, tolerability to DNase digestion and mammalian cell viability compatibility. The N/P ratio 2-chitoplexes revealed the highest green fluorescent protein and luciferase expressions in the transfected mammalian cell cultures and in the mouse lungs. Mice immunized intranasally with the N/P ratio 2-chitoplex vaccines carrying DNAs coding for conserved proteins of influenza virus, i.e., ion channel protein (M2) and/or nucleoprotein (NP), had both mucosal and systemic humoral as well as cell mediated immune responses to the in vivo expressed antigens which conferred protection in mice against the lethal challenges not only with the homologous influenza virus subtype (H1N1), but also the heterologous subtype (H3N2). The chitoplexes should be considered as influenza vaccine candidates especially during the period of high vaccine demand. They are suitable for developing areas of the world where conventional vaccine production capacity is lacking. © 2014 Elsevier B.V.Mahidol UniversityPharmacology, Toxicology and PharmaceuticsIntranasal chitosan-DNA vaccines that protect across influenza virus subtypesArticleSCOPUS10.1016/j.ijpharm.2014.07.005